We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA批准iSCIB1+ DNA疫苗治疗黑色素瘤的三期临床试验。生存率提高24%。了解该药物何时上市以及将帮助哪些患者。
mRNA药物mRNA-4359联合Keytruda显示出83%的应答率和17%的完全缓解。即使是PD-L1阴性肿瘤也缩小了。了解现成疫苗如何教导免疫系统攻击癌症,无需个性化定制。